Clinical trials: Primary Prevention of Cardiovascular Disease
Cardiovascular Diseases, Risk Reduction
Strategy for Cardiovascular Disease Prevention Through Tailored Health Management in Individuals With Elevated Risk
The China PEACE SMARTER trial is a cluster ramdomized trial aiming to assess the effectiveness of village doctor-led tailored health management on risk reduction of high-risk individuals for cardiovascular disease.
- Conditions
- Cardiovascular Diseases, Risk Reduction, Primary Prevention
- Trial name
- SMARTER (NCT05645640)
- Testing
- Village doctor-led tailored health management
- Where
- China
- Volunteers
- 4,533 people
- Sponsor
- China National Center for Cardiovascular Diseases
Glioblastoma
Aspirin Prophylaxis for Venous Thromboembolism in Glioblastoma
Primary objective: To determine whether aspirin (ASA) can lower the incidence of Venous Thromboembolism(VTE) in patients with Glioblastoma (GBM).
- Trial name
- NCT00790452
- Testing
- Aspirin
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- M.D. Anderson Cancer Center
Venous Thromboembolism
BIBR 1048 Dose Range Finding Study in Prevention of Venous Thromboembolism in Patients With Primary Elective Total Hip or Knee Replacement Surgery
The primary objective of this study is to establish the dose-response relationship with regard to efficacy and safety of BIBR 1048 (50 mg bis in die(b.i.d), 150 mg b.i.d, 225 mg b.i.d.
- Trial name
- NCT01225822
- Testing
- Enoxaparin, BIBR 1048
- Where
- 59 sites in Austria, Belgium and 10 more
- Volunteers
- 1,973 people
- Sponsor
- Boehringer Ingelheim
Pancreatic Cancer, Venous Thromboembolism
Dalteparin for Primary Venous Thromboembolism (VTE) Prophylaxis in Pancreatic Cancer Patients
The goal of this clinical research study is to learn if dalteparin can lower the risk of VTE occurring in the legs and lungs. This will be tested in patients with pancreatic cancer who are going to receive chemotherapy.
- Trial name
- NCT00966277
- Testing
- Dalteparin
- Where
- United States
- Volunteers
- 87 people
- Sponsor
- M.D. Anderson Cancer Center
Hereditary Angioedema, HAE
Efficacy and Safety Study of BCX7353 as an Oral Treatment for the Prevention of Attacks in HAE
This is a phase 3, multicenter, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of oral BCX7353 in preventing acute angioedema attacks in patients with Type I and Type II HAE.
- Trial name
- APeX-2 (NCT03485911)
- Testing
- BCX7353 capsules
- Where
- 47 sites in United States, Austria and 9 more
- Volunteers
- 121 people
- Sponsor
- BioCryst Pharmaceuticals
Pregnancy-Associated Hypertension, Gestational Hypertension
Community Health Worker Support to Lower Blood Pressure After a Pregnancy With High Blood Pressure
High blood pressure during or after pregnancy (such as preeclampsia, gestational hypertension, eclampsia, or Hemolysis, Elevated Liver enzymes, and Low Platelet (HELLP) syndrome) raises a mother's risk of heart disease later in…
- Conditions
- Pregnancy-Associated Hypertension, Gestational Hypertension, Preeclampsia, Eclampsia
- Trial name
- AW2H (NCT07778966)
- Testing
- Alabama Womb to Heart Solution (AW2H) Community Health Worker (CHW) Program, Usual postpartum care with self-measured blood pressure education and home blood pressure monitor
- Where
- United States
- Volunteers
- 174 people
- Sponsor
- University of Alabama at Birmingham
Cardiovascular Diseases
HOPE-CVD-Virtual: A Virtual Trial to Evaluate the Primary Prevention of CVD
This 4-arm (1:1:1:1) single-blind randomized controlled trial. Arm 1 will communicate risk and encourage behavioral change that mirrors the standard pathway for health screening in Singapore.
- Trial name
- NCT05827861
- Testing
- HeartAge, HOPE-CVD Mobile App, Genetic Risk Score
- Where
- Singapore
- Volunteers
- 1,121 people, healthy volunteers welcome
- Sponsor
- National University of Singapore
Stroke, Prevention and Control
An Observational Cross-sectional Study Evaluating the Sociodemographic and Clinical Characteristics of Patients Diagnosed With NVAF With a Risk of Stroke or Systemic Embolism, Who Are on Treatment to Adequately Control Their Coagulation and Treated in Primary Care Centres
describe the sociodemographic and clinical characteristics of patients diagnosed with non-valvular atrial fibrillation (NVAF) at risk of stroke or systemic embolism on anticoagulant therapy who have changed their therapeutic…
- Conditions
- Stroke, Prevention and Control, Atrial Fibrillation
- Trial name
- SILVER-AP (NCT02470767)
- Testing
- Direct Oral Anticoagulant (DOAC)
- Where
- Spain
- Volunteers
- 792 people
- Sponsor
- Bayer
Cardiovascular Risk Factor, Cardiovascular Disease
Training Programme in Physical Activity
The primary prevention of cardiovascular disease is an unresolved health problem. A sedentary lifestyle and a low cardiorespiratory condition both increase the risk of cardiovascular disease, at a similar extent as that promoted…
- Trial name
- NCT03717363
- Testing
- Training programme, Educational talk
- Where
- Spain
- Volunteers
- 147 people
- Sponsor
- Hospital Mutua de Terrassa
Stroke
Involvement of the Physician in Primary Prevention and Pre-hospital Management of Stroke
Stroke is a growing disease. It is the first pathology responsible for acquired handicap, the second of dementia and the second cause of death in the world.
- Trial name
- PREVENTION AVC (NCT03975218)
- Testing
- Patients With Stroke
- Where
- France
- Volunteers
- 18 people
- Sponsor
- Fondation Hôpital Saint-Joseph
Myocardial Infarction
Nitroprusside for Prevention of no-Reflow in Primary Angioplasty
In patients admitted with acute myocardial infarction, there is a total occlusion of a coronary artery. Even after emergency catheterization and angioplasty, in some patients, the resumed blood flow is suboptimal and impacts on…
- Trial name
- NCT00128791
- Testing
- Nitroprusside
- Where
- Israel
- Volunteers
- 100 people
- Sponsor
- Soroka University Medical Center
Coronary Artery Disease
Colchicine Use for Primary Prevention of Coronary Artery Disease
Colchicine has been widely used as an anti-gout medicine in the past decades. Some recent clinical trials have proved that low-dose colchicine can be used as a secondary prevention drug for coronary artery disease because of its…
- Trial name
- NCT05175274
- Testing
- Colchicine
- Where
- China
- Volunteers
- 6,792 people
- Sponsor
- Qingdao Central Hospital
Diabetes, Hypertension
Effects of Dengzhanxixin Capsule on Platelet Function in Individuals at High Risk for Cardiovascular Disease
The main objective of this clinical trial is to evaluate whether the antiplatelet efficacy of the Dengzhanxixin capsule is better than that of placebo in individuals at high-risk for atherosclerotic cardiovascular disease (ASCVD).
- Conditions
- Diabetes, Hypertension, Hypercholesterolemia
- Trial name
- FUTURE (NCT05459519)
- Where
- China
- Volunteers
- 165 people, healthy volunteers welcome
- Sponsor
- China National Center for Cardiovascular Diseases
Venous Thromboembolism, Cancer
Tinzaparin for Primary Treatment and Extended Secondary Prophylaxis of Venous Thromboembolism in Patients With Cancer
In this study the investigators will determine the safety and effectiveness of Tinzaparin in preventing blood clots for up to 12 months of treatment.
- Trial name
- NCT00981903
- Testing
- Tinzaparin sodium
- Where
- 2 sites in United States
- Volunteers
- 131 people
- Sponsor
- University of Southern California
Hereditary Angioedema (HAE)
Long-term Safety and Efficacy Study of DX-2930 (SHP643) to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE
This study is an open-label, long term safety and efficacy study to evaluate DX-2930 in preventing acute angioedema attacks in participants with Type I and Type II HAE.
- Trial name
- NCT02741596
- Testing
- DX-2930
- Where
- 43 sites in United States, Canada and 5 more
- Volunteers
- 212 people
- Sponsor
- Shire
Hereditary Angioedema
A Study to Assess the Long-Term Safety and Efficacy of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE)
The purpose of this study is to evaluate the long-term safety and efficacy of donidalorsen in people with HAE and the effects of donidalorsen on the number of HAE attacks and their impact on quality of life (QoL).
- Trial name
- NCT05392114
- Testing
- Donidalorsen
- Where
- 50 sites in United States, Belgium and 12 more
- Volunteers
- 154 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Lipid Metabolism Disorders, Cardiovascular Diseases
Statin Monotherapy or Statins in Combination With Ezetimibe in Patients for Prevention of CVD
Retrospective observational study of the efficacy and safety of statin monotherapy or statins in combination with ezetimibe in patients receiving lipid-lowering therapy in both primary and secondary prevention of cardiovascular…
- Trial name
- UNISON (NCT04895098)
- Testing
- statin and ezetimibe combination therapy, statin monotherapy
- Where
- 31 sites in Russia
- Volunteers
- 1,000 people
- Sponsor
- Akrikhin
Metabolic Syndrome
Cardiovascular Diseases and Diabetes Prevention Programme in Metabolic Syndrome (CDPP)
The metabolic syndrome population is at high-risk of cardiovascular diseases and diabetes. How to effectively control the risk factors of this population is the key to primary prevention of cardiovascular diseases and diabetes in…
- Trial name
- CDPP (NCT05105321)
- Testing
- Berberine, Healthy lifestyle intervention
- Where
- China
- Volunteers
- 5,200 people
- Sponsor
- Tang Yida
Graft Versus Host Disease
Visilizumab for the Prevention of Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation
The purpose of this study was to test whether a new drug named visilizumab would decrease the severity of graft-versus-host disease in patients treated with a mismatched donor.
- Trial name
- NCT00720629
- Testing
- Visilizumab, Tacrolimus, Methotrexate
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Cardiovascular Diseases, Cholesterol, LDL
Reducing Disparities in Primary Prevention of Cardiovascular Disease
Cardiovascular disease (CVD) is the leading cause of disparities in years of life lost by race and low socioeconomic status. Statins have been shown to decrease the risk of cardiovascular events among individuals with high CVD…
- Trial name
- NCT01610609
- Testing
- Population Health Management Intervention
- Where
- 3 sites in United States
- Volunteers
- 646 people
- Sponsor
- Northwestern University